EGFR
Les inhibiteurs du récepteur du facteur de croissance épidermique (EGFR) sont des composés qui bloquent la signalisation de l'EGFR, un récepteur souvent surexprimé dans divers cancers et qui joue un rôle crucial dans l'angiogenèse. Les inhibiteurs de l'EGFR sont utilisés pour prévenir la croissance tumorale et les métastases en perturbant les voies qui favorisent la formation de vaisseaux sanguins dans les tumeurs. Ces inhibiteurs sont largement utilisés dans la recherche et le traitement du cancer. Chez CymitQuimica, nous offrons une sélection diversifiée d'inhibiteurs de l'EGFR de haute qualité pour soutenir vos recherches en oncologie et angiogenèse.
572 produits trouvés pour "EGFR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tarlox-TKI
CAS :<p>Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.</p>Formule :C19H18BrClN6ODegré de pureté :97.03%Couleur et forme :SolidMasse moléculaire :461.74EGFR-IN-69
CAS :<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Formule :C31H37Cl2N7O3SCouleur et forme :SolidMasse moléculaire :658.64EGFR-IN-67
CAS :<p>EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].</p>Formule :C18H17N3SCouleur et forme :SolidMasse moléculaire :307.41EGFR-IN-54
CAS :<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Formule :C17H14N4O4S3Couleur et forme :SolidMasse moléculaire :434.51EGFR-IN-21
CAS :<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Formule :C36H44BrN10O2PCouleur et forme :SolidMasse moléculaire :759.68NSC81111
CAS :<p>NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].</p>Formule :C19H16O4Couleur et forme :SolidMasse moléculaire :308.33EGFR-IN-73
CAS :<p>EGFR-IN-73 (Compound 3f) effectively inhibits the prevalent EGFR mutation, EGFR Del19, exhibiting an IC50 value of 119 nM [1].</p>Formule :C19H17ClFN3O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :405.81Antiproliferative agent-34
CAS :<p>Antiproliferative Agent-34 (Compound A14), a multitarget kinase inhibitor, demonstrates IC50 values of 177 nM for EGFR L858R/T790M and 1567 nM for EGFR WT.</p>Formule :C27H27N7O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :529.55EGFR-IN-89
CAS :<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Formule :C26H31FN8O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :538.64AG-183
CAS :<p>(Z)-Tyrphostin A51, a Z-isomer of Lanoconazole A51, is a strong PTK inhibitor blocking [3 H]taurine release and tyrosyl phosphorylation.</p>Formule :C13H8N4O3Couleur et forme :Brown SolidMasse moléculaire :268.23EGFR-IN-16
CAS :<p>EGFR-IN-16 (AG473) is an inhibitor of EGFR in human A431 cells.</p>Formule :C16H11NO3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :265.26(E/Z)-AG490
CAS :<p>(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.</p>Formule :C17H14N2O3Couleur et forme :SolidMasse moléculaire :294.3EGFR-IN-75
<p>EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.</p>Formule :C10H6N6S2Couleur et forme :SolidMasse moléculaire :274.32CGP52411
CAS :<p>CGP52411 is an orally active, and ATP-competitive inhibitor of EGFR (IC50: 0.3 μM).</p>Formule :C20H15N3O2Degré de pureté :99.78%Couleur et forme :SolidMasse moléculaire :329.35EGFR-IN-50
CAS :<p>EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.</p>Formule :C24H26BrN3O4S2Couleur et forme :SolidMasse moléculaire :564.51EGFR-IN-53
CAS :<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Formule :C14H13N3O2SCouleur et forme :SolidMasse moléculaire :287.34EGFR-IN-28
CAS :<p>EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .</p>Formule :C31H39BrN10O3SCouleur et forme :SolidMasse moléculaire :711.68NSC114126
CAS :<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formule :C22H20O4Couleur et forme :SolidMasse moléculaire :348.39BAY 2476568
CAS :<p>BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).</p>Formule :C24H27FN4O4Couleur et forme :SolidMasse moléculaire :454.49LDC0496
CAS :<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Formule :C32H35N5O3Couleur et forme :SolidMasse moléculaire :537.65Lavendustin C6
CAS :<p>Lavendustin C6 is a effective tyrosine kinase inhibitor.</p>Formule :C20H25NO5Couleur et forme :SolidMasse moléculaire :359.42PDZ1i
CAS :<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Formule :C28H26N8O4Couleur et forme :SolidMasse moléculaire :538.56Nazartinib mesylate
CAS :<p>Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).</p>Formule :C27H35ClN6O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :591.12Tyrphostin AG 112
CAS :<p>Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.</p>Formule :C13H8N4ODegré de pureté :97.01%Couleur et forme :SolidMasse moléculaire :236.23DBPR112
CAS :<p>DBPR112: oral furanopyrimidine EGFR inhibitor; IC50: 15 nM (EGFRWT), 48 nM (L858R/T790M); blocks ATP site, strong antitumor effects.</p>Formule :C32H31N5O3Degré de pureté :99.25%Couleur et forme :SolidMasse moléculaire :533.62Epertinib
CAS :<p>Epertinib is a reversible and selective tyrosine kinase inhibitor of EGFR, HER2, and HER4 (IC50s: 1.48 nM, 7.15 nM, and 2.49 nM).</p>Formule :C30H27ClFN5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :560.02MS 39
CAS :<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Formule :C55H71ClFN9O7SCouleur et forme :SolidMasse moléculaire :1056.72RTC-5
CAS :<p>RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties.</p>Formule :C24H22ClF3N2O3SDegré de pureté :98.14%Couleur et forme :SolidMasse moléculaire :510.96SDZ281-977
CAS :<p>SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor.</p>Formule :C18H20O5Degré de pureté :99.64%Couleur et forme :SolidMasse moléculaire :316.35EGFR-IN-2
CAS :<p>EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.</p>Formule :C26H33N9O3SDegré de pureté :98.52% - 99.79%Couleur et forme :SolidMasse moléculaire :551.66Gefitinib N-oxide
CAS :<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Formule :C22H24ClFN4O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :462.9Nimotuzumab
CAS :<p>Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).</p>Degré de pureté :95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Couleur et forme :LiquidEGFR-IN-5
CAS :<p>EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.</p>Formule :C31H38FN9ODegré de pureté :98.17%Couleur et forme :SolidMasse moléculaire :571.69BKI-1369
CAS :<p>BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).</p>Formule :C23H27N7OCouleur et forme :SolidMasse moléculaire :417.51EGFR-IN-68
CAS :<p>EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.</p>Formule :C24H22N2OCouleur et forme :SolidMasse moléculaire :354.44JBJ-04-125-02
CAS :<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Formule :C29H26FN5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :543.61EGFR mutant-IN-2
CAS :<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Formule :C27H27F3N6O2SCouleur et forme :SolidMasse moléculaire :556.6Mutated EGFR-IN-2
CAS :<p>Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.</p>Formule :C29H35FN8O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :562.64GW 583340 dihydrochloride
CAS :<p>GW 583340 dihydrochloride is a potent and orally available dual EGFR/ErbB2 inhibitor and inhibits 80% of tumor growth in a mouse xenograft mode.</p>Formule :C28H27Cl3FN5O3S2Degré de pureté :98.80%Couleur et forme :SolidMasse moléculaire :671.03EGFR-IN-64
CAS :<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Formule :C20H21N3O3Couleur et forme :SolidMasse moléculaire :351.4JNJ28871063 hydrochloride
CAS :<p>ErbB receptor family inhibitor</p>Formule :C24H28Cl2N6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :519.42Mutated EGFR-IN-3
CAS :<p>Mutated EGFR-IN-3: ATP-competitive, selective dibenzodiazepinone inhibitor for EGFR mutations, IC50 12-13 nM.</p>Formule :C31H29FN4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :508.59EMI48
CAS :<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Formule :C21H20N2O3Couleur et forme :SolidMasse moléculaire :348.4EGFR-IN-39
CAS :<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Formule :C24H25ClN6O3Couleur et forme :SolidMasse moléculaire :480.95Selatinib
CAS :<p>Selatinib is an orally active and potent dual inhibitor of EGFR and ErbB2 with anticancer activity that inhibits the growth of NCI-N87 tumor cells.</p>Formule :C29H26ClFN4O3SDegré de pureté :98.00%Couleur et forme :SolidMasse moléculaire :565.06EMI56
CAS :<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Formule :C21H20N2O3Couleur et forme :SolidMasse moléculaire :348.4EGFR-IN-55
CAS :<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Formule :C25H25Cl2N7O2Couleur et forme :SolidMasse moléculaire :526.42EGFR-IN-49
CAS :<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Formule :C22H15N5O2SCouleur et forme :SolidMasse moléculaire :413.45EGFR-IN-31
CAS :<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Formule :C32H36FN7O2Couleur et forme :SolidMasse moléculaire :569.67EGFR/HER2-IN-3
CAS :<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Formule :C26H23N5O3Couleur et forme :SolidMasse moléculaire :453.49Tyrphostin 51
CAS :<p>Tyrphostin 51 is an effective inhibitor of EGFR kinase.</p>Formule :C13H8N4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :268.23EGFR-IN-25
CAS :<p>EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.</p>Formule :C34H43N9O2Couleur et forme :SolidMasse moléculaire :609.76MS 154N
CAS :<p>MS 154N is a negative control for MS 154, binds WT/L858R EGFR tightly (Kd 3-4.3nM), doesn't trigger mutant EGFR degradation.</p>Formule :C47H56ClFN8O8Couleur et forme :SolidMasse moléculaire :915.45JBJ-09-063 hydrochloride
<p>JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.</p>Formule :C31H30ClFN4O3SCouleur et forme :SolidMasse moléculaire :593.11PD 173955-Analog1
CAS :<p>PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.</p>Formule :C21H14Cl2N4O3Couleur et forme :SolidMasse moléculaire :441.27EGA
CAS :<p>EGA blocks the entry of a variety of other acid-dependent bacterial toxins and viruses into mammalian cells and can be used to treat infectious diseases.</p>Formule :C16H16BrN3ODegré de pureté :98% - 99.6%Couleur et forme :SolidMasse moléculaire :346.22DS21360717
CAS :<p>DS21360717 is an effective oral tyrosine kinase inhibitor with anticancer activity and IC50 of 0.49 nM.</p>Formule :C21H23N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :389.45EGFR/HER2-IN-2
CAS :<p>EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).</p>Formule :C26H23N5O3Couleur et forme :SolidMasse moléculaire :453.49UNC-CA359
CAS :<p>UNC-CA359: potent EGFR inhibitor, IC50=18 nM, strong anti-tumor effect, promising for chordoma.</p>Formule :C18H14ClN3O2Couleur et forme :SolidMasse moléculaire :339.78CAY10717
CAS :<p>CAY10717 inhibits 34/104 kinases at 100 nM, targets EGFR/ABL/B-Raf mutations, kills various cancer cells, and blocks HUVEC growth.</p>Formule :C29H25F3N6O3Couleur et forme :SolidMasse moléculaire :562.54Cloperastine fendizoate
CAS :<p>Cloperastine fendizoate (Hustazol) inhibits the hERG K+ currents in a concentration-dependent manner (IC50: 27 nM).</p>Formule :C40H38ClNO5Degré de pureté :99.97%Couleur et forme :SolidMasse moléculaire :648.19Falnidamol
CAS :<p>Falnidamol (BIBX 1382), an oral selective EGFR inhibitor, IC50 3 nM, weak on ErbB2 and others, anti-cancer pyrimido-pyrimidine.</p>Formule :C18H19ClFN7Degré de pureté :98.816%Couleur et forme :SolidMasse moléculaire :387.84A-935142
CAS :<p>A-935142 enhances hERG (Kv 11.1) channels, slows inactivation, promotes activation, and shortens repolarization.</p>Formule :C18H19F3N2O2Degré de pureté :98.97% - 99.91%Couleur et forme :SolidMasse moléculaire :352.35EMI1
CAS :<p>EMI1 targets mutated EGFR in drug-resistant NSCLC research.</p>Formule :C20H18N2O3Degré de pureté :99.96%Couleur et forme :SolidMasse moléculaire :334.37EGFR-IN-9
CAS :<p>EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M).</p>Formule :C29H24N4O3Degré de pureté :99.8%Couleur et forme :SolidMasse moléculaire :476.53Rezivertinib
CAS :<p>Rezivertinib (BPI-7711) is an EGFR inhibitor with antitumor activity and can be used to study central nervous system diseases.</p>Formule :C27H30N6O3Degré de pureté :99.26% - 99.89%Couleur et forme :SolidMasse moléculaire :486.57Epitinib succinate
CAS :<p>Epitinib succinate (HMPL-813 succinate) is an orally active and brain penetration EGFR tyrosine kinase inhibitor and can be used in studies about cancer.</p>Formule :C28H32N6O6Degré de pureté :98.02% - 99.79%Couleur et forme :SolidMasse moléculaire :548.59Sunvozertinib
CAS :<p>Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2.Cost-effective and quality-assured.</p>Formule :C29H35ClFN7O3Degré de pureté :98.11% - 99.63%Couleur et forme :SolidMasse moléculaire :584.08Tyrphostin A25
CAS :<p>Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.</p>Formule :C10H6N2O3Degré de pureté :98.76%Couleur et forme :Yellow Green Powder /Off-White SolidMasse moléculaire :202.17PD 174265
CAS :<p>PD 174265 is an effective, selective and reversible inhibitor of epidermal growth factor receptor (EGFR) with an IC50 of 0.45 nM.</p>Formule :C17H15BrN4ODegré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :371.23EGFR-IN-99
CAS :<p>EGFR-IN-99 (JBJ-03-142-02) is an EGFR and HER2 Exon 20 insertion mutation inhibitor for the study of non-small cell lung cancer (NSCLC).</p>Formule :C25H22FN7O3Degré de pureté :97.75%Couleur et forme :SolidMasse moléculaire :487.49Larotinib
CAS :<p>Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.</p>Formule :C24H26ClFN4O4Degré de pureté :98.45%Couleur et forme :SolidMasse moléculaire :488.94SKLB 1028
CAS :<p>SKLB 1028, an oral EGFR/FLT3/Abl inhibitor, excels in AML and CML with Abl mutations.</p>Formule :C24H29N9Degré de pureté :99.90% - >99.99%Couleur et forme :SolidMasse moléculaire :443.55PKI-166
CAS :<p>PKI-166: oral EGF-R tyrosine kinase inhibitor (IC50: 0.7 nM), halts growth & spread of many human cancers, including pancreatic.</p>Formule :C20H18N4ODegré de pureté :99.2%Couleur et forme :SolidMasse moléculaire :330.38CGP77675
CAS :<p>CGP77675 (ZINC1488120) is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and</p>Formule :C26H29N5O2Degré de pureté :99.66%Couleur et forme :SolidMasse moléculaire :443.54LY 456236 hydrochloride
CAS :<p>LY 456236 hydrochloride (MPMQ hydrochloride) is an mGlu1 receptor antagonist with an ic50 value of 143 nM.</p>Formule :C16H16ClN3O2Degré de pureté :99.95%Couleur et forme :SolidMasse moléculaire :317.77HKI-357
CAS :<p>HKI-357 irreversibly inhibits EGFR/ERBB2 (IC50: 34/33 nM), blocks EGFR Y1068 autophosphorylation, and AKT/MAPK phosphorylation.</p>Formule :C31H29ClFN5O3Degré de pureté :99.91%Couleur et forme :SolidMasse moléculaire :574.05EGFR-IN-29
CAS :<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Formule :C36H46BrN8O2PCouleur et forme :SolidMasse moléculaire :733.68EGFR-IN-30
CAS :<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Formule :C28H33BrN7O2PCouleur et forme :SolidMasse moléculaire :610.49Labuxtinib
CAS :<p>Labutinib is a selective inhibitor of the c-kit tyrosine kinase [1].</p>Formule :C20H16FN5O2Degré de pureté :99.77%Couleur et forme :SolidMasse moléculaire :377.37EGFR-IN-85
CAS :<p>EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFR</p>Formule :C26H30N8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :486.57BPIQ-I
CAS :<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Formule :C16H12BrN5Couleur et forme :SolidMasse moléculaire :354.2PF-06459988
CAS :<p>PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.</p>Formule :C19H22ClN7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :431.88(Z)-RG-13022
CAS :<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Formule :C16H14N2O2Couleur et forme :SolidMasse moléculaire :266.29EGFR-IN-61
CAS :<p>EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).</p>Formule :C33H37ClN8O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :629.15JGK-068S
CAS :<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Formule :C22H23BrFN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :488.35BEBT-109
CAS :<p>BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.</p>Formule :C27H32N8O3Degré de pureté :97.26%Couleur et forme :SolidMasse moléculaire :516.6DZD1516
CAS :<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Formule :C28H27F2N7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :547.562′-Thioadenosine
CAS :<p>2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM against</p>Formule :C10H13N5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :283.31Lifirafenib
CAS :<p>Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant</p>Formule :C25H17F3N4O3Degré de pureté :98% - 98.25%Couleur et forme :SolidMasse moléculaire :478.42EGFR-IN-71
CAS :<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Formule :C16H9ClIN3Couleur et forme :SolidMasse moléculaire :405.62HER2-IN-5
CAS :<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Formule :C27H33N7O3Couleur et forme :SolidMasse moléculaire :503.6EGFR-IN-32
CAS :<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Formule :C31H34N6O3Couleur et forme :SolidMasse moléculaire :538.64BGB-102
CAS :<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Formule :C22H25BrN4O2Degré de pureté :99.02%Couleur et forme :SolidMasse moléculaire :457.36EGFR/CSC-IN-1
CAS :<p>EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potential</p>Formule :C54H54Cl2FN7O7S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1067.08JND3229
CAS :<p>JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.</p>Formule :C33H41ClN8O2Degré de pureté :98.75%Couleur et forme :SolidMasse moléculaire :617.18EGFR-IN-36
CAS :<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Formule :C26H25ClN6O2Couleur et forme :SolidMasse moléculaire :488.97BMS-599626 Hydrochloride
CAS :<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Formule :C27H28ClFN8O3Degré de pureté :99.98%Couleur et forme :SolidMasse moléculaire :567.01PAT-505
CAS :<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Formule :C23H18ClF2N3O2SDegré de pureté :98.84%Couleur et forme :SolidMasse moléculaire :473.92EGFR mutant-IN-1
<p>EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.</p>Formule :C34H39ClFN7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :632.17
